Articles From: Bio-Techne Announces Agreement To Acquire Novus Biologicals to BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting


MINNEAPOLIS , July 2, 2014 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) (d/b/a Bio-Techne) announced today that it has acquired Novus Biologicals for $60 million in cash.
Sign-up for Bio-Techne Announces Agreement To Acquire Novus Biologicals investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Announces Appointment Of Brenda Furlow As General Counsel investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Announces ProteinSimple Acquisition Completion investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Declares Dividend investment picks
MINNEAPOLIS , Aug.
Sign-up for Bio-Techne Releases Fourth Quarter And Full Year 2014 Results investment picks
LAS VEGAS , Aug.
Sign-up for BioAdaptives Announces First Product to Market investment picks
LAS VEGAS , July 17, 2014 /PRNewswire/ -- BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Dr.
Sign-up for BioAdaptives Equine Development Success and Advisory Board Addition investment picks
2014/7/9
BioAdaptives, Inc. cleared by FINRA for quotation on OTC Bulletin Board and OTC Link under the symbol BDPT LAS VEGAS , July 9, 2014 /PRNewswire/ -- BioAdaptives, Inc. (OTC BB: BDPT) announced that it is cleared by FINRA for quotation on OTC Bulletin Board and OTC Link under the symbol BDPT effective as of July 8 , 2014.
Sign-up for BioAdaptives OTC Bulletin Board Symbol: BDPT investment picks
MINNEAPOLIS , July 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that the underwriters of its common stock offering exercised in full their option to purchase an additional 420,000 shares of common stock at the public offering price of $12.00 per share, less underwriting discounts and commissions, in connection with its previously announced underwritten public offering of 2,800,000 shares of common stock, bringing the expected net proceeds from the offering to approximately $35.8 million , after deducting expenses of BioAmber and underwriting discounts and commissions.
Sign-up for BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering investment picks
MINNEAPOLIS, MN , July 18, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing renewable chemicals, announced today that it will report its financial results for the second quarter 2014 on Thursday August 7, 2014 .
Sign-up for BioAmber Announces Webcast of Fiscal Second Quarter 2014 Financial Results investment picks
BioAmber Inc. announces pricing of $33.6 million registered offering Canada NewsWire MINNEAPOLIS, MN , July 16, 2014 /CNW/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that it has priced an underwritten registered offering of 2,800,000 shares of its common stock at a price of $12.00 per share, and granted the underwriters in the offering a 30-day option to purchase up to an additional 420,000 shares of its common stock.
Sign-up for BioAmber Inc. announces pricing of $33.6 million registered offering investment picks
MINNEAPOLIS, MN , July 16, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that it has priced an underwritten registered offering of 2,800,000 shares of its common stock at a price of $12.00 per share, and granted the underwriters in the offering a 30-day option to purchase up to an additional 420,000 shares of its common stock.
Sign-up for BioAmber Inc. announces pricing of $33.6 million registered offering investment picks
BioAmber Inc. announces public offering of common stock Canada NewsWire MINNEAPOLIS, MN , July 15, 2014 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that it has commenced a public offering of 2,800,000 shares of its common stock.
Sign-up for BioAmber Inc. announces public offering of common stock investment picks
MINNEAPOLIS, MN , July 15, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that it has commenced a public offering of 2,800,000 shares of its common stock.
Sign-up for BioAmber Inc. announces public offering of common stock investment picks
BioAmber Reports Second Quarter 2014 Financial Results Canada NewsWire MINNEAPOLIS, MN , Aug.
Sign-up for BioAmber Reports Second Quarter 2014 Financial Results investment picks
MINNEAPOLIS, MN , Aug.
Sign-up for BioAmber Reports Second Quarter 2014 Financial Results investment picks
MINNEAPOLIS, MN , July 2, 2014 BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that its Canadian subsidiary BioAmber Sarnia Inc., a Joint Venture with Mitsui & Co., has secured a CDN $7 million grant from Sustainable Development Technology Canada (SDTC). The funds will be used to support the ongoing construction of the CDN$135 million ( US$125 million ) bio-succinic acid plant that is under construction in Sarnia Ontario.
Sign-up for BioAmber Secures $7 Million Grant From SDTC investment picks
MINNEAPOLIS, MN , June 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced that its Canadian subsidiary BioAmber Sarnia Inc., a joint venture with Mitsui & Co., has secured a CAD$20 million commercial loan from a financial consortium led by Export Development Canada and including Farm Credit Canada and Comerica Bank.
Sign-up for BioAmber Secures CAD$20 Million Loan for Sarnia Plant investment picks
BioAmber Signs Take-or-Pay Contract For Three Bio-Succinic Acid Plants Canada NewsWire Vinmar commitment is for 210,000 tons of succinic acid per year when three plants operational Contract guarantees sale of 10,000 tons per year for 15 years from Sarnia plant in construction 50% of Sarnia capacity is under take-or-pay, with total contracted demand exceeding capacity Previously announced 100,000 ton per year BDO plant will be expanded to also produce 70,000 tons per year of succinic acid, with Vinmar off-taking 100% of the BDO produced and 70% of the bio-succinic acid produced for 15 years Vinmar also commits to off-take 75% of the production from a new, third bio-succinic acid plant with 200,000 MT per year capacity that BioAmber currently plans to startup in 2020 Vinmar commits to a 10% or greater equity investment in each of the next two plants MINNEAPOLIS, MN , July 7, 2014 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) , an
Sign-up for BioAmber Signs Take-or-Pay Contract For Three Bio-Succinic Acid Plants investment picks
Vinmar commitment is for 210,000 tons of succinic acid per year when three plants operational Contract guarantees sale of 10,000 tons per year for 15 years from Sarnia plant in construction 50% of Sarnia capacity is under take-or-pay, with total contracted demand exceeding capacity Previously announced 100,000 ton per year BDO plant will be expanded to also produce 70,000 tons per year of succinic acid, with Vinmar off-taking 100% of the BDO produced and 70% of the bio-succinic acid produced for 15 years Vinmar also commits to off-take 75% of the production from a new, third bio-succinic acid plant with 200,000 MT per year capacity that BioAmber currently plans to startup in 2020 Vinmar commits to a 10% or greater equity investment in each of the next two plants MINNEAPOLIS, MN , July 7, 2014 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA) , an industrial biotechnology company producing sustainable chemicals, today announced it has signed a
Sign-up for BioAmber Signs Take-or-Pay Contract For Three Bio-Succinic Acid Plants investment picks
TEL AVIV, Israel, Aug.
Sign-up for BioBlast Pharma Reports Second Quarter Financial Results investment picks
TEL AVIV, Israel, Sept.
Sign-up for BioBlast to Ring the NASDAQ Stock Market Opening Bell investment picks
SAN DIEGO, Aug.
Sign-up for Biocept Provides Second Quarter Operational Update investment picks
SAN DIEGO, Sept.
Sign-up for Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe investment picks
SAN DIEGO, Sept.
Sign-up for Biocept to Present at Upcoming Investor Conferences investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Bio-Techne Announces Agreement To Acquire Novus Biologicals to BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices